S
Stephen R. Marder
Researcher at University of California, Los Angeles
Publications - 418
Citations - 36674
Stephen R. Marder is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Schizophrenia & Schizophrenia (object-oriented programming). The author has an hindex of 87, co-authored 406 publications receiving 33103 citations. Previous affiliations of Stephen R. Marder include University of Texas Southwestern Medical Center & University of Saskatchewan.
Papers
More filters
Journal ArticleDOI
Practice guideline for the treatment of patients with schizophrenia
Marvin I. Herz,Robert Paul Liberman,T. H. McGlashan,Jeffrey A. Lieberman,Richard Jed Wyatt,Stephen R. Marder,P. Wang,C. Allgulander,Ross J. Baldessarini,R. Balon,A. S. Bellack,C M Jr Berlin,C. H. Blackington,Peter F. Buckley,D. G. Carlson,J. Cott,Francine Cournos,P. Desai,L. Dickstein,Wayne Fenton,W. A. Fisher,Lois T. Flaherty,R. Freedman,Marc Galanter,E. Galton,Rohan Ganguli,L. K. Garrettson,S. Goldfinger,L. S. Goldman,M. Z. Goldstein,T. R. Gordy,S. H. Gray,Monica R. Green,W. M. Greenberg,John G. Gunderson,L. L. Hall,E. Haller,E. Hanin,L. Hawkins,T. W. Hester,T. Horn,J. K. Hsiao,N. V. Juthani,John M. Kane,A. Kayser,H. D. Kibel,R. A. Kimmich,R. R. Koegler,J. Krajeski,T. Kuehnel,J.S. Lamberti,Anthony F. Lehman,J. Leunello,R. L. Martin,R. McCarley,Mark McGee,Herbert Y. Meltzer,M.-Marsel Mesulam,Jeffrey L. Metzner,Loren R. Mosher,J. A. Motto,Kim T. Mueser,R. A. Munoz,H. A. Nasrallah,J. W. Newcomer,Lewis A. Opler,G. N. Peterson,M. Rapaport,Michelle Riba,V. I. Rickert,A. Rifkin,J. S. Rivenbark,S. Robertson,P. Ruiz,W. G. Ryan,M. O. Sanderson,R. B. Schiffer,P. M. Schyve,R. H. Sebring,W. W. Shen,D. Shore,G. M. Simpson,H. E. Soufi,L. I. Stein,N. Stotland,J. Strauss,D. Sundberg,D. Svendsen,Mauricio Tohen,M. Tsuang,J. G. Wagnitz,Richard D. Weiner,W. D. Weitzel,L. J. Wilkerson,D. Wingerson,C A Jr Zarate,J. Zito,Howard Zonana +97 more
Journal ArticleDOI
Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus
Nancy C. Andreasen,William T. Carpenter,John M. Kane,Robert A. Lasser,Stephen R. Marder,Daniel R. Weinberger +5 more
TL;DR: The first consensus-based operational criteria for symptomatic remission in schizophrenia are based on distinct thresholds for reaching and maintaining improvement, as opposed to change criteria, allowing for alignment with traditional concepts of remission in both psychiatric and nonpsychiatric illness.
Journal ArticleDOI
The MATRICS Consensus Cognitive Battery, Part 1: Test Selection, Reliability, and Validity
Keith H. Nuechterlein,Michael F. Green,Robert S. Kern,Lyle E. Baade,M Deanna,Jonathan D. Cohen,Susan M. Essock,Wayne S. Fenton,Frederick J. Frese,James M. Gold,Terry E. Goldberg,Robert K. Heaton,Richard S.E. Keefe,Helena C. Kraemer,Raquelle I. Mesholam-Gately,Larry J. Seidman,Ellen Stover,Daniel R. Weinberger,Alexander S. Young,Steven Zalcman,Stephen R. Marder +20 more
TL;DR: The MATRICS Consensus Cognitive Battery is expected to be the standard tool for assessing cognitive change in clinical trials of cognition-enhancing drugs for schizophrenia and may also aid evaluation of cognitive remediation strategies.
Journal ArticleDOI
Risperidone in the treatment of schizophrenia.
TL;DR: The results indicate that the optimal daily dose of risperidone for most schizophrenic patients in this study was 6 mg; this dose was as effective as 16 mg, and the incidence of extrapyramidal symptoms in patients receiving 6 mg of ris peridone was no higher than that in Patients receiving placebo.
Journal ArticleDOI
The NIMH-MATRICS Consensus Statement on Negative Symptoms
TL;DR: A consensus development conference was held to review the data relating to the existence of separate domains within negative symptoms, as a prerequisite for choosing appropriate measures of these domains in clinical trials and to examine issues that may interfere with treatment development.